Literature DB >> 16531051

Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats.

Marianne Husson1, Valérie Enderlin, André Delacourte, Nadirah Ghenimi, Serge Alfos, Véronique Pallet, Paul Higueret.   

Abstract

Recent data have revealed that disruption of vitamin A signaling observed in Alzheimer's disease (AD) leads to a deposition of beta-amyloid (Abeta). The aim of this study was to precise the role of vitamin A and its nuclear receptors (RAR) in the processes leading to the Abeta deposits. Thus, the effect of vitamin A depletion and subsequent administration of retinoic acid (RA, the active metabolite of vitamin A) on the expression of RARbeta, and of proteins involved in amyloidogenic pathway, e.g., amyloid precursor protein (APP), beta-secretase enzyme (BACE), and APP carboxy-terminal fragment (APP-CTF) was examined in the whole brain, hippocampus, striatum, and cerebral cortex of rats. Rats fed a vitamin A-deprived diet for 13 weeks exhibited decreased amount of RARbeta, APP695, BACE, and of APP-CTF in the whole brain and in the cerebral cortex. Administration of RA is able to restore all expression. The results suggest that fine regulation of vitamin A mediated gene expression seems fundamental for the regulation of APP processing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531051     DOI: 10.1016/j.nbd.2006.01.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  20 in total

Review 1.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Why should plasma transthyretin become a routine screening tool in elderly persons?

Authors:  Y Ingenbleek
Journal:  J Nutr Health Aging       Date:  2009-08       Impact factor: 4.075

Review 3.  Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence.

Authors:  Niyaz Mohammadzadeh Honarvar; Ahmad Saedisomeolia; Mina Abdolahi; Amir Shayeganrad; Gholamreza Taheri Sangsari; Babak Hassanzadeh Rad; Gerald Muench
Journal:  J Mol Neurosci       Date:  2016-11-18       Impact factor: 3.444

Review 4.  Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines.

Authors:  Liliana Letra; Isabel Santana; Raquel Seiça
Journal:  Metab Brain Dis       Date:  2014-02-20       Impact factor: 3.584

Review 5.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

6.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 7.  Drug repositioning for Alzheimer's disease.

Authors:  Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

8.  Retinoic acid receptor-α signalling antagonizes both intracellular and extracellular amyloid-β production and prevents neuronal cell death caused by amyloid-β.

Authors:  C I Jarvis; M B Goncalves; E Clarke; M Dogruel; S B Kalindjian; S A Thomas; M Maden; J P T Corcoran
Journal:  Eur J Neurosci       Date:  2010-10       Impact factor: 3.386

9.  Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential.

Authors:  Markus Uhrig; Peter Brechlin; Olaf Jahn; Yuri Knyazev; Annette Weninger; Laura Busia; Kamran Honarnejad; Markus Otto; Tobias Hartmann
Journal:  BMC Med       Date:  2008-12-16       Impact factor: 8.775

Review 10.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.